AAM
MRNA icon

Advisors Asset Management’s Moderna MRNA Stock Holding History

Advisors Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Sell
4,346
-442
-9% -$20.6K ﹤0.01% 1132
2025
Q4 		$141K Sell
4,788
-129
-3% -$3.5K ﹤0.01% 1180
2025
Q3 		$127K Sell
4,917
-63
-1% -$1.76K ﹤0.01% 1190
2025
Q2 		$137K Sell
4,980
-70
-1% -$1.84K ﹤0.01% 1161
2025
Q1 		$143K Sell
5,050
-236
-4% -$8.38K ﹤0.01% 1146
2024
Q4 		$220K Buy
5,286
+546
+12% +$26.1K ﹤0.01% 1104
2024
Q3 		$317K Buy
4,740
+971
+26% +$89.1K 0.01% 1030
2024
Q2 		$448K Buy
3,769
+2,134
+131% +$270K 0.01% 929
2024
Q1 		$174K Sell
1,635
-95
-5% -$9.58K ﹤0.01% 1157
2023
Q4 		$172K Sell
1,730
-4,688
-73% -$394K ﹤0.01% 1133
2023
Q3 		$663K Sell
6,418
-750
-10% -$83.7K 0.01% 829
2023
Q2 		$871K Sell
7,168
-2,050
-22% -$273K 0.02% 787
2023
Q1 		$1.42M Sell
9,218
-629
-6% -$104K 0.03% 628
2022
Q4 		$1.77M Sell
9,847
-4,136
-30% -$676K 0.04% 539
2022
Q3 		$1.65M Buy
13,983
+338
+2% +$51.3K 0.03% 555
2022
Q2 		$1.95M Buy
13,645
+2,803
+26% +$401K 0.04% 519
2022
Q1 		$1.87M Buy
10,842
+2,532
+30% +$426K 0.03% 608
2021
Q4 		$2.11M Buy
8,310
+1,903
+30% +$556K 0.03% 591
2021
Q3 		$2.47M Buy
6,407
+488
+8% +$180K 0.04% 529
2021
Q2 		$1.39M Buy
5,919
+1,031
+21% +$184K 0.02% 714
2021
Q1 		$640K Buy
4,888
+1,590
+48% +$230K 0.01% 958
2020
Q4 		$345K Buy
3,298
+362
+12% +$36.6K 0.01% 1078
2020
Q3 		$208K Sell
2,936
-6,848
-70% -$477K ﹤0.01% 1172
2020
Q2 		$628K Buy
9,784
+6,437
+192% +$353K 0.01% 827
2020
Q1 		$100K Sell
3,347
-63
-2% -$1.45K ﹤0.01% 1225
2019
Q4 		$67K Buy
3,410
+11
+0.3% +$195 ﹤0.01% 1374
2019
Q3 		$54K Sell
3,399
-7,549
-69% -$112K ﹤0.01% 1388
2019
Q2 		$160K Buy
+10,948
New +$235K ﹤0.01% 1224

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advisors Asset Management's MRNA Position: Q1 2026 in Review

Advisors Asset Management reduced its Moderna (MRNA) stake by 9.2% in Q1 2026, selling an estimated $20.6K and leaving 4,346 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #1132.

Advisors Asset Management first reported a position in MRNA in Q2 2019 and has held it in 28 quarters since. The position peaked at $2.47M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Advisors Asset Management held 4,346 shares of Moderna worth $221K as of Q1 2026.
  • Advisors Asset Management sold 442 Moderna shares in Q1 2026, an estimated $20.6K.
  • Moderna made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1132 holding.
  • Advisors Asset Management first reported a position in Moderna in Q2 2019 and has held it in 28 quarters since.
  • Advisors Asset Management's Moderna position peaked at $2.47M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.